Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$9.58 USD
-0.08 (-0.83%)
Updated May 28, 2024 04:00 PM ET
After-Market: $9.58 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth F Momentum D VGM
Brokerage Reports
Amicus Therapeutics, Inc. [FOLD]
Reports for Purchase
Showing records 61 - 80 ( 171 total )
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Post KOL Call and Model Updates Following Debt Financing
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Glycosylation Enhances FVC and 6MWT in Pivotal Study; Positive Implications for PROPEL
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revisiting AT-GAA, Other rhGAA''s, and Implications for the PROPEL Phase 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Good Global Resilience Despite the Obvious Headwinds
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D